Rebif: Phase III data; marketed in Europe

AREB presented previously reported 4-year follow-up data from its 560-patient international PRISMS trial showing that high dose Rebif is significantly superior to low dose therapy in reducing relapses and delaying disease progression (see BioCentury, March 6). Data were presented at the American Academy of Neurology meeting in San Diego. ...